Barcode Nanotech
Jerusalem, Israel· Est.
Israeli platform biotech enabling precise RNA delivery via AI‑driven in‑vivo nanoparticle screening.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Israeli platform biotech enabling precise RNA delivery via AI‑driven in‑vivo nanoparticle screening.
OncologyMetabolic DiseaseVaccines
Technology Platform
Proprietary lipid nanoparticles combined with an AI‑driven in‑vivo mass‑screening platform that uses molecular barcoding to assess biodistribution and target specificity at single‑cell resolution.
Opportunities
Scalable, AI‑enhanced nanoparticle screening could attract pharma partners seeking tissue‑specific RNA delivery, opening revenue streams through licensing and co‑development.
Risk Factors
Technical validation of targeting claims, regulatory uncertainties for novel delivery systems, and competition from established LNP platforms may delay commercialization.
Competitive Landscape
Competes with Moderna, BioNTech, Alnylam, and other LNP developers; differentiation lies in the high‑throughput in‑vivo barcoding screen that promises faster, more precise formulation optimization.